Vnitr Lek 2007, 53(3):223-225

Humorální rejekce po transplantaci ledviny - editorial

J. Zadražil
III. interní klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Vlastimil Ščudla, CSc.

Received: December 1, 2006; Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zadražil J. Humorální rejekce po transplantaci ledviny - editorial. Vnitr Lek. 2007;53(3):223-225.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Terasaki P, Mizutani K. Antibody mediated rejection. Update 2006. Clin J Am Soc Nephrol 2006; 1: 400-403. Go to original source... Go to PubMed...
    2. Halloran PF, Wadgymar A, Ritchie S et al. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990; 49: 85-91. Go to original source... Go to PubMed...
    3. Halloran PF, Schlaut J, Solez K et al. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550-555. Go to original source... Go to PubMed...
    4. Feucht HE, Schneeberger H, Hillebrand G et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338. Go to original source... Go to PubMed...
    5. Zwirner J, Felber E, Herzog V et al. Classical pathway of complement activation in normal and disease human glomeruli. Kidney Int 1989; 36: 1069-1077. Go to original source... Go to PubMed...
    6. Collins AB, Schneeberger EE, Pascua MA et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214. Go to original source... Go to PubMed...
    7. Sun Q, Liu Z, Yin G et al. Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases. Transplantation 2005; 79: 1759-1762. Go to original source... Go to PubMed...
    8. Regele H, Exner M, Watschinger B et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 10: 2058-2066. Go to original source... Go to PubMed...
    9. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection kriteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714. Go to original source... Go to PubMed...
    10. Mauiyyedi J, Crespo M, Collins AB et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779-787. Go to original source... Go to PubMed...
    11. Tinckam KJ, Chandraker A. Mechanisms and role of HLA and non-HLA alloantibodies. Clin J Am Soc Nephrol 2006; 1: 404-414. Go to original source... Go to PubMed...
    12. Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041. Go to original source... Go to PubMed...
    13. Montgomery RA, Hardy MA, Jordan SC et al. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78: 181-185. Go to original source... Go to PubMed...
    14. Mengel M, Bogers J, Bosmans JL et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant 2005; 5: 1050-1056. Go to original source... Go to PubMed...
    15. Becker Y T, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int 2006; 19: 621-628. Go to original source... Go to PubMed...
    16. Dragun D, Muller DN, Brasen JH et al. Angiotensin II type l-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569. Go to original source... Go to PubMed...
    17. Muro M, Llorente S, Marin L et al. Acute vascular rejection mediated by HLA antibodies in a cadaveric kidney recipient: discrepancies between FlowPRATM, ELISA and CDC vs luminex screening. Nephrol Dial Transplant 2005; 20: 223-226. Go to original source... Go to PubMed...
    18. Martin L, Guignier F, Bocrie O et al. Detection of anti-HLA antibodies with flow cytometry in needle core biopsies of renal transplant recipients with chronic allograft nephropathy. Transplantation 2005; 79: 1459-1461. Go to original source... Go to PubMed...
    19. Zhang Q, Liang LW, Gjertson DW et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005; 79: 591-598. Go to original source... Go to PubMed...
    20. Herzenberg AM, Gill JS, Djurdjev O et al. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol 2002; 13: 234-241. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.